Science

CENTER FOR INFECTIOUS DISEASE POLICY AND RESEARCH by Lisa Schnirring     July 20, 2015

Tekmira Pharmaceuticals  announced that it has suspended development of TKM-Ebola, a drug cocktail that showed disappointing human trial results in West Africa, as a convalescent plasma trial at a Doctors Without Borders (MSF) facility in Guinea proceeded with no ill effects in patients so far...

In suspending TKM-Ebola development, the company said that a joint reevaluation of its contract with the US Department of Defense is under way.

In another development, MSF said a convalescent serum trial at its facility in Nongo, Guinea, has enrolled 101 people over the last few months, with no ill effects reported so far, according to a Jul 17 update on the outbreak. Patients at the Nongo treatment unit have the option to receive plasma donated by Ebola survivors....

Meanwhile, detailed testing at a Swiss hospital on a 43-year-old doctor infected with Ebola in Sierra Leone found that viral decay occurred in two phases, once starting 72 hours after symptom onset before any antiviral interventions, with acceleration in viral load decay after ZMAb infusion and oral favipiravir treatments began..

Read complete article.

REUTERS by Gene Emery                                                                         June 18, 2015

The warning is based on a single case and the woman did not actually spread the deadly infection to anyone. But laboratory tests revealed high levels of the virus when no symptoms were present.

Usually people aren't considered to be contagious until they start to feel ill.

The reason pregnant women may be an exception may have to do with the way pregnancy affects the woman's body, the doctors say. Her immune system becomes more tolerate of the fetus, whose tissues would normally be considered foreign.

Read complete story.
http://news.yahoo.com/pregnant-ebola-patient-may-contagious-days-without-symptoms-124114264.html;_ylt=AwrC0wxAAYNVTlEAmp7QtDMD;_ylu=X3oDMTBybGY3bmpvBGNvbG8DYmYxBHBvcwMyBHZ0aWQDBHNlYwNzcg--

CHEMISTRY WORLD by Christopher Barnard             June 17, 215
The virulence of Ebola virus strains appears to be innately linked to the degree of disorder in proteins that form their nucleocapsids. Computational analysis has revealed that strains responsible for the most lethal outbreaks of Ebola show significantly higher levels of intrinsic protein disorder than less virulent strains, in a discovery that could constitute a major breakthrough in understanding the pathogen’s behaviour.

With over 27,000 confirmed, probable and suspected cases and more than 11,000 fatalities worldwide, the ongoing Ebola outbreak has resulted in considerably more casualties since late 2013 than all other outbreaks combined. There are no effective treatments or vaccines against the haemorrhagic fever that evinces Ebola infection; however, strains of the virus with drastically different virulence have emerged since the first outbreak in 1976, with fatality rates ranging from 25 to 90%.

PLOS by Arlene C. Chua,Jane Cunningham,Francis Moussy, Mark D. Perkins,and Pierre Formenty      June 11 2015

 ...Since the identification of Ebola in Guinea in March 2013, rapid deployment of international mobile laboratories through WHO networks—Global Outbreak Alert and Response Network (GOARN) [2] and Emerging and Dangerous Pathogens Laboratory Network (EDPLN) [3]—has been vital to outbreak control operations. Deployable laboratories from multiple international organizations have been established near Ebola treatment centers (ETC) in Guinea, Liberia, and Sierra Leone....

However, several technical and social factors conspire to delay diagnosis, starting with weak surveillance systems and slow patient access to centralized ETCs. While the mean processing time is 5 hours (time difference from when samples are received in the laboratory to when they are tested), there is a marked difference in the time from when the samples are collected from suspected patients to the time they are received by the laboratory